Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit dips below year-ago levels

Q1 FY2026 gross profit of $40.93M fell 17.7% year over year, behind the +39.8% change in trailing-twelve-month gross profit. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at -10.0% a year.

Context

  • Gross profit amounted to 83.3% of revenue in FY2025, up 22.7 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -17.7% toward the trailing-twelve-month pace of +39.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$40.93M-9.9% QoQ
Last fiscal yearDec 2025
$196.73M+102.8% YoY
LTMMar 2026
$187.95M+39.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.7%——
1 year+102.8%——
3-year CAGR-10.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
196.73M USD
Year-over-year change
+102.8%
4-year CAGR
+10.9%

Gross Profit vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 gross profit of $187.95M is the 2nd highest of the 10 companies compared; the peer median is $27.14M.
  • Its year-over-year change of +39.8% is the 4th highest of 7, against a peer median of -0.9%.
  • Gross profit amounts to 80.9% of revenue for AKBA, versus a peer median of 88.8%.
AKBA Competitors Peer median
Gross Profit for AKBA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$279.95M +53.8%+32.3%93.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$187.95M +39.8%-10.0%80.9%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$106.66M ——92.0%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$104.57M +226.8%+108.4%85.5%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.3M -55.6%—99.6%
PRTAProthena Corporation plcLTM Mar 2026$27.14M -80.3%-51.9%46.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K ———
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$306K ———
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$738K -186.8%——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$10.98M +90.3%—12.4%
Peer median (excluding AKBA) $27.14M-0.9%+32.3%88.8%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue211.65M292.48M194.62M160.18M236.2M
Cost of Revenue81.49M22.5M74.15M63.18M39.46M
Gross Profit130.16M269.99M120.47M97M196.73M
Gross Margin61.5%92.3%61.9%60.6%83.3%
Research & Development147.85M165.99M63.08M37.65M62.36M
Selling, General & Admin174.14M138.6M100.23M106.55M107.48M
Operating Expenses394.66M350.77M166.73M147.48M173.24M
Depreciation & Amortization37.97M37.7M37.63M37.5M1.27M
EBITDA(189.91M)3.06M(8.27M)(13.72M)21.73M
EBITDA Margin-89.7%1.0%-4.2%-8.6%9.2%
Operating Income(264.5M)(80.78M)(46.26M)(50.47M)23.5M
Operating Margin-125.0%-27.6%-23.8%-31.5%9.9%
Interest Income00000
Interest Expense19.94M15.69M6.03M18.19M24.18M
Other Income / Expenses(17.52M)(13.45M)(5.67M)(18.94M)(27.22M)
Income Before Tax(282.02M)(94.23M)(51.93M)(69.41M)(3.72M)
Pre-Tax Margin-133.3%-32.2%-26.7%-43.3%-1.6%
Income Tax Expense00001.62M
Net Income(282.02M)(94.23M)(51.93M)(69.41M)(5.35M)
Net Margin-133.3%-32.2%-26.7%-43.3%-2.3%
EPS (Basic)(1.48)(0.58)(0.28)(0.33)(0.02)
EPS (Diluted)(1.48)(0.58)(0.28)(0.33)(0.02)
Weighted Avg Shares165.95M182.78M187.47M210.95M257.16M
Weighted Avg Shares (Diluted)165.95M182.78M187.47M210.95M257.16M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.